Table 2.

Characteristics by development of BCRL

	N	Y	Total	p
N	194	21	215
Age at baseline				0.297
Mean (SD)	60.5 (12.8)	63.6 (12)	60.8 (12.7)
Median	62	65	62
Range	24, 89	41, 88	24, 89
BMI high	86 (49%)	11 (58%)	97 (50%)	0.613
Final type of surgery M	83 (45%)	10 (53%)	93 (45%)	0.670
Final type of axillary surgery SLNB	164 (88%)	12 (63%)	176 (85%)	0.011
Adjuvant Y	42 (22%)	7 (33%)	49 (23%)	0.348
Neo adjuvant Y	8 (4%)	2 (10%)	10 (5%)	0.568
Taxane Y	43 (22%)	7 (33%)	50 (23%)	0.379
Targeted (herceptin or TKI) Y	8 (4%)	1 (5%)	9 (4%)	1.000
WB Y	94 (48%)	14 (67%)	108 (50%)	0.175
Regional nodal irradiation Y	33 (17%)	8 (38%)	41 (19%)	0.041
APBI Y	20 (10%)	0 (%)	20 (9%)	0.250

ALND axillary lymph node dissection, SLNB sentinel lymph node biopsy, BMI body mass index, TKI tyrosine kinase inhibitor, WB whole breast irradiation, APBI accelerated partial breast irradiation